Does the antidepressant-like effect of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane involve a regulation of β-type estrogen receptors?
These data demonstrate that the antidepressant-like potential of trilostane is not due to its 3β-HSD inhibiting activity, since it is not shared by cyanoketone, but rather to its estrogenic activity. The compound, which releases estradiol and up-regulates ERβ receptors, could be used as a therapeutic tool to allow an estrogenic facilitation of antidepressant efficacy.
IL-37 plays a critical role in inhibiting LPS-induced DCs activation via suppressing production of co-stimulatory molecules CD80, CD86 and pro-inflammatory cytokines.